{
    "nctId": "NCT00537771",
    "briefTitle": "Liver Safety Under Upfront Arimidex vs Tamoxifen",
    "officialTitle": "A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 384,
    "primaryOutcomeMeasure": "Incidence of Fatty Liver Disease",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven HR+ invasive breast cancer\n* Completed all primary surgery and chemotherapy (if given), and were candidates to receive hormonal adjuvant therapy\n* Postmenopausal woman\n\nExclusion Criteria:\n\n* clinical evidence of metastatic disease\n* previous adjuvant hormonal therapy for breast cancer\n* liver diseases",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}